Research map: Real-World Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Pharmacovigilance Study

Back to the article

Papers in this map

  1. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy · Matthew J. Maurer · 2018 · 2849 citations · Cited by this paper
  2. Effects of Exercise Training on Left Ventricular Hypertrophy and Cardiac Regulation in Elite Athletes: Insight from a Composite Index Proxy of Autonomic Control · 2026 · Related
  3. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports · Stephen Evans · 2001 · 1826 citations · Cited by this paper
  4. Clinical and Economic Implications of High-Sensitivity Troponin-Informed Admission Strategies in Non-AMI Chest Pain · 2026 · Related
  5. A Bayesian neural network method for adverse drug reaction signal generation · Andrew M. Bate · 1998 · 1480 citations · Cited by this paper
  6. Predictive Performance of the HEART Score for Acute Coronary Syndrome with Significant Coronary Stenosis in Patients with Non–ST-Elevation Acute Chest Pain · 2026 · Related
  7. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis · Michelle Maya Kittleson · 2023 · 631 citations · Cited by this paper
  8. Evolving Proteomic Biomarkers in Children with Congenital Heart Defects · 2026 · Related
  9. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy · Julian David Gillmore · 2024 · 535 citations · Cited by this paper
  10. From Valve Anatomy to Molecular Trajectories: Integrating Proteomics into Precision Care for Bicuspid Aortic Valve Disease · 2026 · Related
  11. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction · Thomas M. Maddox · 2024 · 307 citations · Cited by this paper
  12. Time-Cumulative Residual Cardiovascular Risk in Patients with Coronary Heart Disease and Diabetes: A 10-Year Follow-Up Study from a Large-Scale Population Cohort and an Independent Clinical Validation Cohort · 2026 · Related
  13. Cardiac Amyloidosis Due to Transthyretin Protein · Frederick L. Ruberg · 2024 · 247 citations · Cited by this paper
  14. Feasibility of On-Site CT-FFR Analysis in Ruling Out In-Stent Restenosis on Cardiac PCCT · 2026 · Related
  15. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events · G. Niklas Norén · 2005 · 208 citations · Cited by this paper
  16. Biomarkers of Cardiovascular Stress: A Historical Review · 2026 · Related
  17. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands · Candan Kendir · 2017 · 106 citations · Cited by this paper
  18. Neuroprognostication After Extracorporeal Cardiopulmonary Resuscitation: ECMO-Specific Challenges and a Multimodal Time-Sensitive Framework · 2026 · Related
  19. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials · Daniela Tomasoni · 2023 · 39 citations · Cited by this paper
  20. A Digital Model to Explain the Necessity of Prostaglandin E1 After Balloon Atrial Septostomy in D-Transposition of the Great Arteries · 2026 · Related
  21. Haemodynamic frailty – A risk factor for acute kidney injury in the elderly · Neil Gerard Docherty · 2021 · 31 citations · Cited by this paper
  22. Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags · Janna Margaretha Siemer · 2025 · 9 citations · Cited by this paper
  23. Differential Binding Affinities and Kinetics of Transthyretin Stabilizers · Alan X. Ji · 2025 · 8 citations · Cited by this paper
  24. Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support · Gang Ye · 2025 · 5 citations · Cited by this paper
  25. Untitled · Cited by this paper

Source: OpenAlex (CC0)